US4117117A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Tridecapetide having gastrin effect
Assignee: Max-Planck-Gesellschaft zur Förderung der Wissenschaften eV
•
Filing: 1977-06-21
•
Granted: 1978-09-26
•
Expires: 1997-06-21
Abstract
Abstract The tridecapeptide having the general formula L-leucyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-alanyl-L-tyrosylglycyl-L-tryptophyl-L-leucyl-L-asparagyl-L-phenylalanineamide, or a salt or protected derivative thereof. Such tridecapeptide has gastrin activity. A process of preparation of such tridecapeptide, a process of use of it, and thereapeutic or diagnostic agents incorporating it.
Inventors
- 👤 Erich Wunsch
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-11-03 08:58
CPC Classifications
C; C07; C07K; C07K14/00; C07K14/435; C07K14/575; C07K14/595; A; A61; A61P; A61P1/00; A61P1/14; A61K; A61K38/00; Y; Y10; Y10S; Y10S930/00; Y10S930/01; Y10S930/29
Claims Analysis
Total Claims: 18
Claim 1
Independent Claim
14 words
The tridecapeptide having the general formula L-leucyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-alanyl-L-tyrosyl-glycyl-L-tryptophyl-L-leucyl-L-asparagyl-L-phenylalanineamide, or a salt or protected derivative thereof.
Claim 2
Dependent Claim
14 words
The tridecapeptide having the general formula L-leucyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-alanyl-L-tyrosyl-glycyl-L-tryptophyl-L-leucyl-L-asparagyl-L-phenylalanineamide, or a salt or protected derivative thereof.
Claim 3
Dependent Claim
8 words
The tridecapeptide of claim 1, in unprotected form.
Claim 4
Dependent Claim
10 words
The tridecapeptide of claim 1 which is a salt thereof.
Claim 5
Dependent Claim
12 words
The tridecapeptide salt of claim 3 which is an ammonium salt thereof.
Claim 6
Dependent Claim
18 words
The tridecapeptide of claim 1 which has amino protective groups or amide protective groups or carbonyl protective groups.
Claim 7
Dependent Claim
10 words
A composition containing L-leucyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-alanyl-L-tyrosylglycyl-L-tryptophyl-L-leucyl-L-asparagyl-L-phenylalanineamide and/or a pharmaceutically acceptable salt thereof.
Claim 8
Dependent Claim
10 words
A composition containing L-leucyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-alanyl-L-tyrosylglycyl-L-tryptophyl-L-leucyl-L-asparagyl-L-phenylalanineamide and/or a pharmaceutically acceptable salt thereof.
Claim 9
Dependent Claim
17 words
Process wherein the composition of claim 6 is used to stimulate the HCI secretion of the stomach.
Claim 10
Dependent Claim
18 words
Process wherein the composition of claim 6 is used to determine the HCI secretion capacity of the stomach.
Claim 11
Dependent Claim
14 words
Process wherein L-leucyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-alanyl-L-tyrosyl-glycyl-L-tryptophyl-L-leucyl-L-asparagyl-L-phenylalanine-amide is used to make an immunological determination of gastrin or minigastrin.
Claim 12
Dependent Claim
14 words
Process wherein L-leucyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-glutamyl-L-alanyl-L-tyrosyl-glycyl-L-tryptophyl-L-leucyl-L-asparagyl-L-phenylalanine-amide is used to make an immunological determination of gastrin or minigastrin.
Claim 13
Dependent Claim
12 words
The tridecapeptide of claim 3 which is a pharmaceutically acceptable salt thereof.
Claim 14
Dependent Claim
25 words
The tridecapeptide of claim 3 wherein said salt is with a base selected from the group consisting of ammonia, sodium hydroxide, potassium hydroxide and dimethylamine.
Claim 15
Dependent Claim
51 words
The tridecapeptide of claim 1 wherein said tridecapeptide has amino protective groups selected from the group consisting of formyl, phthalyl, trifluoroacetyl, p-tosyl, aryl phosphoryl, alkyl phosphoryl, phenyl sulfonyl, benzyl sulfonyl, tritysulfenyl, o-nitrophenylsulfenyl, γ-chlorobutyryl, o-nitrophenoxyacetyl, trityl, benzyl, alkylidene, carbobenzoxy, p-bromo, p-chloro or p-methoxycarbobenoxy, tolyloxy, allyloxy, cyclopentyloxy, cyclohexyloxy, t-butloxy, 1,1-dimethylpropyloxy,2-(p-biphenyl)-2-propyloxy-carbonyl, benzylthiocarbonyl and 1-adamantyloxycarbonyl.
Claim 16
Dependent Claim
23 words
The tridecapeptide of claim 1 wherein said tridecapeptide has amide protective groups selected from the group consisting of xanthenyl, 2,4-dimethoxybenzyl, 2,4,6-trimethoxybenzyl and 4,4'-dimethoxybenzhydryl.
Claim 17
Dependent Claim
39 words
The tridecapeptide of claim 1 wherein said tridecapeptide has carboxyl protective groups selected from the group consisting of methyl, ethyl, t-butyl, benzyl, cyanomethyl, phthalimidomethyl, 4-picolyl-, 2-p-tosyl ethyl, phenyl, p-nitrophenyl, thiophenyl or p-nitrobenzyl ester and trityl phenyl, carbobenzoxy or t-butoxycarbonylhydrazide.
Claim 18
Dependent Claim
28 words
A composition as claimed in claim 6 wherein said tridecapeptide is in mixture with an organically or inorganically inert carrier material suitable for the enteric or parentereol application.
References Cited (Backward Citations)
DE2256445A1
Cited
US3931141A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1981-09-25 | 1982-03-27 | 1982-09-26 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1985-09-25 | 1986-03-27 | 1986-09-26 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1989-09-25 | 1990-03-27 | 1990-09-26 | $7700.00 | Window Closed / Lapsed |